• Maira Riaz, Shahnila Hafeez, Mohsina Noor Ibrahim, Zubair Ahmed Khoso, Taj Muhammad Laghari Br, and Syed Jamal Raza.
• J Coll Physicians Surg Pak. 2022 Sep 1; 32 (9): 1165-1169.

ObjectiveTo evaluate the efficacy and safety of zoledronic acid in children with osteogenesis imperfecta (OI).Study DesignDescriptive Study.Place And Duration Of StudyNational Institute of Child Health, Department of Endocrine and Diabetes, Karachi, Pakistan, from January 2011 to December 2020.MethodologyChildren, with OI registered for the treatment, were included. Zoledronic acid was given to them by intravenous infusion over 30 minutes with a dose of 0.05 mg/Kg/day for a median duration of 60 (24-96) months. To ensure safety, patients were kept for 24 hours after dose administration to monitor any short-term side effects. The patients were assessed after every 3-6 months for frequency of fracture, bone pain, and BMD.ResultOut of 82 children [40 females (48.8%) and 42 males (51.2%)], 11 patients (13.4%) had fever and 2 patients (2.4%) had flu-like illness. No other side effects were observed. The annual fracture rate decreased overall from 2.8±1.5 to 0.2±0.5 (˂0.001) in both males (2.6±1.3 to 0.1±0.4) and females (3.1±1.7 to 0.2±0.6). Z-score on DEXA scan showed improvement in BMD overall (-3.9±2.0 to 2.2 ±1.7), in males (-3.7±1.9 to -2.1±1.7) and in females (4.1±2.1 to -2.3±1.8). There were no other long-term side effects like ocular problems, osteonecrosis of the jaw, and delayed healing of the fractures.ConclusionZoledronate use in children is associated with minimal short-term and long-term side effects with a significant improvement in BMD and decline in fracture rate.Key WordsOsteogenesis imperfecta (OI), Bisphosphonates (BPs), DEXA scan, Bone mineral density (BMD).

16 keywords...

hide…